CL2014001174A1 - Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades. - Google Patents

Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades.

Info

Publication number: CL2014001174A1
Authority: CL; Chile
Prior art keywords: triazolo; glaucoma; prophylaxis; atherosclerosis; pyrimidine
Prior art date: 2011-11-08

Application number

CL2014001174A

Other languages

English (en)

Inventor

Caterina Bissantz

Uwe Grether

Atsushi Kimbara

Stephan Roever

Jean-Michel Adam

Mattias Nettekoven

Mark Rogers-Evans

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-08

Filing date

2014-05-06

Publication date

2014-09-12

2014-05-06 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2014-09-12 Publication of CL2014001174A1 publication Critical patent/CL2014001174A1/es

Links

GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical compound N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 title 1
201000001320 Atherosclerosis Diseases 0.000 title 1
208000010412 Glaucoma Diseases 0.000 title 1
206010061218 Inflammation Diseases 0.000 title 1
208000002193 Pain Diseases 0.000 title 1
208000032109 Transient ischaemic attack Diseases 0.000 title 1
229940121376 cannabinoid receptor agonist Drugs 0.000 title 1
239000003537 cannabinoid receptor agonist Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000004054 inflammatory process Effects 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
238000011321 prophylaxis Methods 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
201000010875 transient cerebral ischemia Diseases 0.000 title 1
238000011282 treatment Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hematology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)

CL2014001174A 2011-11-08 2014-05-06 Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades. CL2014001174A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP11188333		2011-11-08

Publications (1)

Publication Number	Publication Date
CL2014001174A1 true CL2014001174A1 (es)	2014-09-12

Family

ID=47116003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014001174A CL2014001174A1 (es)	2011-11-08	2014-05-06	Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades.

Country Status (31)

Country	Link
US (2)	US8741906B2 (es)
EP (1)	EP2776442B1 (es)
JP (1)	JP6138141B2 (es)
KR (1)	KR102032337B1 (es)
CN (1)	CN103930426B (es)
AR (1)	AR088663A1 (es)
AU (1)	AU2012334173B2 (es)
BR (1)	BR112014011055B1 (es)
CA (1)	CA2850458C (es)
CL (1)	CL2014001174A1 (es)
CO (1)	CO6920295A2 (es)
CY (1)	CY1117147T1 (es)
DK (1)	DK2776442T3 (es)
EA (1)	EA023581B1 (es)
ES (1)	ES2553704T3 (es)
HR (1)	HRP20160052T1 (es)
HU (1)	HUE025543T2 (es)
IL (1)	IL231949A (es)
MX (1)	MX342309B (es)
MY (1)	MY170878A (es)
PE (1)	PE20141588A1 (es)
PH (1)	PH12014500813A1 (es)
PL (1)	PL2776442T3 (es)
PT (1)	PT2776442E (es)
RS (1)	RS54436B1 (es)
SG (1)	SG11201402197UA (es)
SI (1)	SI2776442T1 (es)
TW (2)	TWI704150B (es)
UA (1)	UA111640C2 (es)
WO (1)	WO2013068306A1 (es)
ZA (1)	ZA201402905B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA111640C2 (uk) *	2011-11-08	2016-05-25	Ф. Хоффманн-Ля Рош Аг	ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
US9067943B2 (en) *	2011-11-25	2015-06-30	Hoffmann-La Roche Inc.	[1,2,3]triazolo[4,5-D]pyrimidine derivatives
CN105143220B (zh)	2013-03-07	2018-06-22	豪夫迈·罗氏有限公司	吡唑衍生物
PE20151559A1 (es)	2013-03-26	2015-11-05	Hoffmann La Roche	Nuevos derivados de piridina
BR112015027394A8 (pt)	2013-05-02	2018-01-30	Hoffmann La Roche	derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2
HRP20181141T1 (hr)	2013-05-02	2018-09-21	F. Hoffmann - La Roche Ag	Derivati purina kao agonisti cb2 receptora
AU2014317229B2 (en) *	2013-09-06	2018-11-08	F. Hoffmann-La Roche Ag	Novel triazolo(4,5-d)pyrimidine derivatives
MY195016A (en) *	2014-08-04	2023-01-03	Nuevolution As	Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
CA2960794A1 (en)	2014-11-07	2016-05-12	F. Hoffmann-La Roche Ag	Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
EP3294745B1 (en) *	2015-05-08	2020-01-01	H. Hoffnabb-La Roche Ag	Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection
CN105541738B (zh) *	2016-01-21	2018-04-06	西北师范大学	一种三氮唑取代的苯乙酮类化合物的制备方法
JP7090036B2 (ja)	2016-06-23	2022-06-23	エフ．ホフマン－ラロシュアーゲー	新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体
CN109311886B (zh)	2016-06-23	2021-11-09	豪夫迈·罗氏有限公司	[1,2,3]三唑并[4,5-d]嘧啶衍生物
JP7090037B2 (ja) *	2016-06-23	2022-06-23	エフ．ホフマン－ラロシュアーゲー	新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体
CR20220661A (es) *	2016-06-23	2023-02-21	Hoffmann La Roche	NUEVOS DERIVADOS DE [1,2,3]TRIAZOLO[4,5-D]PIRIMIDINA (Divisional 2018-0615)
EP3840854A4 (en) *	2018-08-20	2022-06-29	Bessor Pharma, LLC	Novel cannabinoids and cannabinoid acids and their derivatives
US11814734B2 (en)	2019-05-13	2023-11-14	Ecolab Usa Inc.	1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
AU2020405446A1 (en)	2019-12-20	2022-05-26	Nuevolution A/S	Compounds active towards nuclear receptors
BR112022012205A2 (pt)	2019-12-20	2022-09-13	Nuevolution As	Compostos ativos para receptores nucleares
JP7713954B2 (ja)	2020-03-31	2025-07-28	ヌエヴォリューション・アクティーゼルスカブ	核内受容体に対して活性な化合物
CA3174252A1 (en)	2020-03-31	2021-10-07	Nuevolution A/S	Compounds active towards nuclear receptors
US20230279006A1 (en) *	2020-07-08	2023-09-07	Klotho Therapeutics, Inc.	Novel compounds and methods for increasing klotho gene expression
WO2022106669A1 (en)	2020-11-23	2022-05-27	F. Hoffmann-La Roche Ag	New process for the manufacture of tetrazole derivatives
JP2024542997A (ja)	2021-10-28	2024-11-19	エフ．ホフマン－ラロシュアーゲー	［１，２，３］トリアゾロ［４，５－ｄ］ピリミジンの合成
IL316701A (en)	2022-06-07	2024-12-01	Hoffmann La Roche	Process for preparing 1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol
JP2025531720A (ja)	2022-09-01	2025-09-25	エフ．ホフマン－ラロシュアーゲー	抗ｃｂ２抗体及び細胞表面ｃｂ２発現を測定するためのフローサイトメトリーアッセイにおけるそれらの使用
CN119768171A (zh) *	2022-09-01	2025-04-04	豪夫迈·罗氏有限公司	维卡纳宾的剂量方案

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4076711A (en) *	1976-04-05	1978-02-28	Schering Corporation	Triazolo [4,5-d]-pyrimidines
US5204353A (en) *	1987-04-07	1993-04-20	Ciba-Geigy Corporation	3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
NZ274978A (en) *	1993-10-12	1998-04-27	Du Pont Merck Pharma	1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
JP3398152B2 (ja) *	1993-10-12	2003-04-21	ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー	１ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
WO2008076810A2 (en)	2006-12-14	2008-06-26	Bristol-Myers Squibb Company	Azabicyclic heterocycles as cannabinoid receptor modulators
US7655685B2 (en)	2007-11-02	2010-02-02	Jenrin Discovery, Inc.	Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
AU2008345225A1 (en) *	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
US8598184B2 (en) *	2008-03-03	2013-12-03	Tiger Pharmatech	Protein kinase inhibitors
AR080711A1 (es) *	2010-03-31	2012-05-02	Lilly Co Eli	Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
UA111640C2 (uk) *	2011-11-08	2016-05-25	Ф. Хоффманн-Ля Рош Аг	ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
US9067943B2 (en) *	2011-11-25	2015-06-30	Hoffmann-La Roche Inc.	[1,2,3]triazolo[4,5-D]pyrimidine derivatives

2012
- 2012-05-11 UA UAA201406094A patent/UA111640C2/uk unknown
- 2012-11-05 AU AU2012334173A patent/AU2012334173B2/en active Active
- 2012-11-05 SI SI201230368T patent/SI2776442T1/sl unknown
- 2012-11-05 KR KR1020147015045A patent/KR102032337B1/ko active Active
- 2012-11-05 SG SG11201402197UA patent/SG11201402197UA/en unknown
- 2012-11-05 HR HRP20160052TT patent/HRP20160052T1/hr unknown
- 2012-11-05 MX MX2014005184A patent/MX342309B/es active IP Right Grant
- 2012-11-05 PL PL12780208T patent/PL2776442T3/pl unknown
- 2012-11-05 RS RS20150807A patent/RS54436B1/sr unknown
- 2012-11-05 BR BR112014011055-7A patent/BR112014011055B1/pt active IP Right Grant
- 2012-11-05 JP JP2014540410A patent/JP6138141B2/ja active Active
- 2012-11-05 EP EP12780208.0A patent/EP2776442B1/en active Active
- 2012-11-05 HU HUE12780208A patent/HUE025543T2/en unknown
- 2012-11-05 PE PE2014000649A patent/PE20141588A1/es active IP Right Grant
- 2012-11-05 CA CA2850458A patent/CA2850458C/en active Active
- 2012-11-05 MY MYPI2014701156A patent/MY170878A/en unknown
- 2012-11-05 WO PCT/EP2012/071788 patent/WO2013068306A1/en not_active Ceased
- 2012-11-05 CN CN201280054639.7A patent/CN103930426B/zh active Active
- 2012-11-05 EA EA201490912A patent/EA023581B1/ru unknown
- 2012-11-05 DK DK12780208.0T patent/DK2776442T3/en active
- 2012-11-05 PT PT127802080T patent/PT2776442E/pt unknown
- 2012-11-05 PH PH1/2014/500813A patent/PH12014500813A1/en unknown
- 2012-11-05 ES ES12780208T patent/ES2553704T3/es active Active
- 2012-11-06 US US13/669,610 patent/US8741906B2/en active Active
- 2012-11-06 AR ARP120104159A patent/AR088663A1/es active IP Right Grant
- 2012-11-07 TW TW106134768A patent/TWI704150B/zh active
- 2012-11-07 TW TW101141431A patent/TWI639600B/zh active
2014
- 2014-03-28 CO CO14067070A patent/CO6920295A2/es active IP Right Grant
- 2014-04-03 IL IL231949A patent/IL231949A/en active IP Right Grant
- 2014-04-11 US US14/250,781 patent/US9056866B2/en active Active
- 2014-04-22 ZA ZA2014/02905A patent/ZA201402905B/en unknown
- 2014-05-06 CL CL2014001174A patent/CL2014001174A1/es unknown
2016
- 2016-01-19 CY CY20161100050T patent/CY1117147T1/el unknown

Also Published As

Publication number	Publication date
PT2776442E (pt)	2015-11-18
KR102032337B1 (ko)	2019-10-15
AU2012334173A8 (en)	2014-04-10
WO2013068306A1 (en)	2013-05-16
US9056866B2 (en)	2015-06-16
UA111640C2 (uk)	2016-05-25
DK2776442T3 (en)	2015-11-09
US20130116236A1 (en)	2013-05-09
CA2850458C (en)	2016-10-25
ES2553704T3 (es)	2015-12-11
SG11201402197UA (en)	2014-09-26
MX2014005184A (es)	2014-05-28
TW201825496A (zh)	2018-07-16
HK1194732A1 (zh)	2014-10-24
AR088663A1 (es)	2014-06-25
BR112014011055B1 (pt)	2022-01-11
RS54436B1 (sr)	2016-06-30
TWI639600B (zh)	2018-11-01
HRP20160052T1 (hr)	2016-02-12
PL2776442T3 (pl)	2016-04-29
HUE025543T2 (en)	2016-03-29
JP2014532739A (ja)	2014-12-08
CN103930426B (zh)	2016-05-11
PH12014500813A1 (en)	2016-06-17
PE20141588A1 (es)	2014-10-25
IL231949A (en)	2016-02-29
IL231949A0 (en)	2014-05-28
SI2776442T1 (sl)	2015-12-31
NZ622652A (en)	2015-08-28
KR20140097289A (ko)	2014-08-06
BR112014011055A2 (pt)	2017-05-02
CN103930426A (zh)	2014-07-16
US20140288046A1 (en)	2014-09-25
JP6138141B2 (ja)	2017-05-31
TWI704150B (zh)	2020-09-11
AU2012334173B2 (en)	2017-06-08
MX342309B (es)	2016-09-26
CA2850458A1 (en)	2013-05-16
EP2776442B1 (en)	2015-10-21
AU2012334173A1 (en)	2014-04-03
CY1117147T1 (el)	2017-04-05
EA201490912A1 (ru)	2014-09-30
EA023581B1 (ru)	2016-06-30
ZA201402905B (en)	2016-01-27
CO6920295A2 (es)	2014-04-10
US8741906B2 (en)	2014-06-03
MY170878A (en)	2019-09-11
TW201333011A (zh)	2013-08-16
EP2776442A1 (en)	2014-09-17

Publication	Publication Date	Title
CL2016000495A1 (es)	2016-10-07	Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades.
CL2014002412A1 (es)	2015-03-06	Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
ECSP20070854A (es)	2020-12-31	Compuestos heteroaril tetracíclicos
PE20180318A1 (es)	2018-02-09	Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
MX2019004685A (es)	2019-08-21	Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer.
CO7131357A2 (es)	2014-12-01	Compuestos de n-ariltriazol como antagonistas de lpar
CO2017004525A2 (es)	2017-08-10	Dihidropirrolopiridinas inhibidoras de ror-gamma
CO7131358A2 (es)	2014-12-01	Compuestos de n-alquiltriazol como antagonistas de lpar
CL2016001895A1 (es)	2016-12-09	Compuestos
CL2014000566A1 (es)	2014-10-10	Compuestos derivados de pirrolopirimidina y purina, y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende, util para el tratamiento del crecimiento celular anormal, tal como cancer.
MX2016014308A (es)	2017-01-27	Compuestos y composiciones como agonistas del receptor tipo toll 7.
CL2014000746A1 (es)	2014-10-03	Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
CO6620050A2 (es)	2013-02-15	Derivados de aminopirimidina como moduladores de la lrrk2
CR20150472A (es)	2016-01-04	USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2014003388A1 (es)	2015-04-10	Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
CL2015002635A1 (es)	2016-02-19	Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR20170077A (es)	2017-06-26	Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2015001538A1 (es)	2015-10-23	Compuestos derivados de piridin-2-amidas, agonistas cb2; proceso de preparacion; composicion farmaceutica que los contiene; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras.
ECSP14013215A (es)	2014-05-31	Compuestos novedosos
UY36003A (es)	2015-09-30	Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
CL2015003195A1 (es)	2016-06-03	Derivados de purina como agonistas del receptor cb2.
CL2014001309A1 (es)	2014-10-17	Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras.
DOP2015000170A (es)	2015-08-16	Compuestos químicos
CL2015003196A1 (es)	2016-06-03	Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2.
MX377180B (es)	2025-03-07	Compuestos de pirimidina como inhibidores de la quinasa jak.